The short answer
REDEFINE 4, registered as NCT06131437, randomised 809 adults to CagriSema or tirzepatide 15 mg over 84 weeks. Its primary objective was to confirm non-inferiority of CagriSema, and that objective was not met, 23.0% against 25.5% on the efficacy estimand.
Key facts
- Registration
- NCT06131437
- Sponsor
- Novo Nordisk A/S
- Phase
- 3
- Enrolment
- 809
- Design
- Randomised, masking none (open-label)
- Arms
- CagriSema 2.4/2.4 mg vs tirzepatide 15 mg
- Started
- 27 November 2023
- Completed
- 9 January 2026
- Efficacy estimand
- 23.0% vs 25.5%
- Treatment-policy estimand
- 20.2% vs 23.6%
- Primary endpoint
- Non-inferiority (not met)
What the registry says
The ClinicalTrials.gov record states the official title as an efficacy and safety study of cagrilintide 2.4 mg with semaglutide 2.4 mg once weekly compared to tirzepatide 15 mg. Phase 3, 809 participants, randomised, masking none. Started 27 November 2023, primary completion 8 December 2025, completed 9 January 2026. The primary outcome is written as confirming non-inferiority of CagriSema versus tirzepatide on relative change in body weight.
What was reported
On the efficacy estimand (which asks what happens if everyone adheres) CagriSema reached 23.0% and tirzepatide 25.5%. On the treatment-policy estimand, which counts everyone regardless of adherence, the figures were 20.2% and 23.6%. The primary objective of demonstrating non-inferiority was not met.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What that does and does not mean
It means non-inferiority was not demonstrated. It does not mean inferiority was demonstrated. Those are different findings, and coverage describing CagriSema as bested by or falling to its comparator collapses the distinction. It also does not mean CagriSema failed to work: 23.0% is a large weight reduction by any standard the field had before 2022.
The estimand gap is worth reading
Within this one trial, from the same participants, the two estimands differ by 2.8 points for CagriSema and 1.9 for tirzepatide. Nothing about the drugs changes between those numbers. Only how discontinuation is handled. A figure quoted without stating which estimand produced it cannot be compared with anything.
The design limitation
Masking none. Participants and investigators knew which drug was being given, and body weight is an outcome behaviour influences. Blinding two injectables with different devices and side-effect profiles is hard, so this is a practical constraint rather than an oversight, but it weakens the comparison and belongs beside the numbers.
Why running it at all was notable
Head-to-head trials against a strong comparator are risky, and this one produced a public result the sponsor did not want. Novo Nordisk ran it anyway, at a time when prescribers and payers increasingly expect direct evidence rather than cross-trial comparison.
What this has no bearing on
Research material. Tirzepatide is a licensed medicine; CagriSema is filed and unapproved. Both were administered in a registered trial under clinical supervision. Nothing supplied here is related to either, is an alternative to either, or is described by these results.
Frequently asked questions
Did CagriSema fail?
It did not meet its primary endpoint of non-inferiority. It still produced 23.0% weight reduction on the efficacy estimand, which is a large effect.
Why are two sets of numbers reported?
Two estimands. The efficacy estimand assumes adherence; the treatment-policy estimand counts everyone regardless. Same participants, different handling of discontinuation.
Was the trial blinded?
No. The registry lists allocation as randomised and masking as none.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- TrialClinicalTrials.gov · Cagrilintide with semaglutide compared to tirzepatide, Phase 3 (NCT06131437)clinicaltrials.gov
- RefNovo Nordisk: news and company announcementsnovonordisk.com
- PubMedHamarsheh S et al., Comparative effectiveness of CagriSema, semaglutide, cagrilintide and tirzepatide. Endocrinol Diabetes Metab 2026 (PMID 42207966)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- CagriSema After REDEFINE 4A failed head-to-head does not block an approval. What regulators actually assess, and what changed for CagriSema in February 2026.
- Searching a Trial Name Often Finds the Wrong TrialREDEFINE 4 has no acronym in ClinicalTrials.gov - searching for it returns REDEFINE 1, 2 and 3. How to find and check a registration properly.
- Accelerated Approval Is a Conditional StatementApproval on a surrogate endpoint, with confirmatory evidence required afterwards. Why that is a genuinely different decision from a standard approval.
- What the MHRA Found in a Northampton WarehouseOctober 2025: tens of thousands of empty pens, raw ingredients and over 2,000 unlicensed retatrutide and tirzepatide pens ready for dispatch.
- The Scale of UK Medicines EnforcementAlmost 20 million doses and nearly £45m of illegal medicines seized in 2025, including more than 5,000 illegally traded GLP-1 products.